Regulation
FiberSense plans CGM’s commercial readiness following CE mark
FiberSense has obtained CE mark approval for its continuous glucose monitoring (CGM) device, which uses optical sensor technology to measure glucose in subcutaneous tissue fluid. The company plans next steps toward commercial readiness following the regulatory clearance.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network